High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$0
$0
Total Sells (Filtered)
$18.3M
$18,298,126
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
|
XENE
S
Xenon Pharmaceuticals Inc.
KENNEY CHRISTOPHER JOHN
• Officer • Chief Medical Officer
Sell to CoverΔOwn -37.0%
2026-03-10
$166,559
|
||||||
| XENE |
Xenon Pharmaceuticals Inc.
|
Officer • Chief Medical Officer
Sell to CoverΔOwn -37.0%
|
2026-03-10 | $166,559 | S | Form 4 |
|
XENE
S
Xenon Pharmaceuticals Inc.
DiFabio Andrea
• Officer • Chief Legal Officer
Sell to CoverΔOwn -34.8%
2026-03-10
$156,702
|
||||||
| XENE |
Xenon Pharmaceuticals Inc.
|
Officer • Chief Legal Officer
Sell to CoverΔOwn -34.8%
|
2026-03-10 | $156,702 | S | Form 4 |
| XENE |
Xenon Pharmaceuticals Inc.
|
CEO
Sell to CoverΔOwn -43.3%
|
2026-03-10 | $677,357 | S | Form 4 |
|
XENE
S
Xenon Pharmaceuticals Inc.
MORTIMER IAN
• CEO
10b5-1 SellΔOwn -53.5%
2026-03-09
$1,897,837Large
|
||||||
| XENE |
Xenon Pharmaceuticals Inc.
|
CEO
10b5-1 SellΔOwn -53.5%
|
2026-03-09 | $1,897,837Large | S | Form 4 |
|
XENE
S
Xenon Pharmaceuticals Inc.
MORTIMER IAN
• CEO
10b5-1 SellΔOwn -78.2%
2026-03-09
$1,301,442Large
|
||||||
| XENE |
Xenon Pharmaceuticals Inc.
|
CEO
10b5-1 SellΔOwn -78.2%
|
2026-03-09 | $1,301,442Large | S | Form 4 |
| XENE |
Xenon Pharmaceuticals Inc.
|
CEO
Other
|
2026-03-09 | $77,500 | M | Form 4 |
| XENE |
Xenon Pharmaceuticals Inc.
|
CEO
10b5-1 SellΔOwn -40.2%
|
2026-03-09 | $742,500 | S | Form 4 |
| XENE |
Xenon Pharmaceuticals Inc.
|
CEO
10b5-1 SellΔOwn -29.0%
|
2026-03-09 | $150,026 | S | Form 4 |
| XENE |
Xenon Pharmaceuticals Inc.
|
CEO
Other
|
2026-03-09 | $498,750 | M | Form 4 |
|
XENE
S
Xenon Pharmaceuticals Inc.
MORTIMER IAN
• CEO
10b5-1 SellΔOwn -37.4%
2026-03-09
$2,568,802Large
|
||||||
| XENE |
Xenon Pharmaceuticals Inc.
|
CEO
10b5-1 SellΔOwn -37.4%
|
2026-03-09 | $2,568,802Large | S | Form 4 |
|
XENE
S
Xenon Pharmaceuticals Inc.
MORTIMER IAN
• CEO
10b5-1 SellΔOwn -91.1%
2026-03-09
$3,704,052Large
|
||||||
| XENE |
Xenon Pharmaceuticals Inc.
|
CEO
10b5-1 SellΔOwn -91.1%
|
2026-03-09 | $3,704,052Large | S | Form 4 |
| XENE |
Xenon Pharmaceuticals Inc.
|
CEO
Other
|
2026-03-09 | $613,600 | M | Form 4 |
|
XENE
S
Xenon Pharmaceuticals Inc.
MORTIMER IAN
• CEO
10b5-1 SellΔOwn -91.5%
2026-03-09
$4,033,900Large
|
||||||
| XENE |
Xenon Pharmaceuticals Inc.
|
CEO
10b5-1 SellΔOwn -91.5%
|
2026-03-09 | $4,033,900Large | S | Form 4 |
| XENE |
Xenon Pharmaceuticals Inc.
|
CEO
10b5-1 SellΔOwn -54.4%
|
2026-03-09 | $609,054 | S | Form 4 |
| XENE |
Xenon Pharmaceuticals Inc.
|
CEO
Other
|
2026-03-09 | $630,000 | M | Form 4 |
|
XENE
S
Xenon Pharmaceuticals Inc.
MORTIMER IAN
• CEO
10b5-1 SellΔOwn -26.9%
2026-03-09
$1,281,529Large
|
||||||
| XENE |
Xenon Pharmaceuticals Inc.
|
CEO
10b5-1 SellΔOwn -26.9%
|
2026-03-09 | $1,281,529Large | S | Form 4 |
| XENE |
Xenon Pharmaceuticals Inc.
|
CEO
10b5-1 Sell
|
2025-11-28 | $4,366 | S | Form 4 |
|
XENE
S
Xenon Pharmaceuticals Inc.
MORTIMER IAN
• CEO
10b5-1 SellΔOwn -44.4%
2025-10-01
$1,004,000Large
|
||||||
| XENE |
Xenon Pharmaceuticals Inc.
|
CEO
10b5-1 SellΔOwn -44.4%
|
2025-10-01 | $1,004,000Large | S | Form 4 |
| XENE |
Xenon Pharmaceuticals Inc.
|
CEO
Other
|
2025-10-01 | $192,250 | M | Form 4 |